Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Amgen Inc. is conducting a clinical study titled A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis. The study aims to establish the pharmacokinetic and pharmacodynamic similarities between ABP 692 and Ocrelizumab, focusing on their effects on brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS).
The interventions being tested include ABP 692 and Ocrelizumab (both US and EU versions), administered via intravenous infusion. These drugs are designed to treat RRMS by reducing new active brain lesions.
The study is interventional, randomized, and follows a parallel assignment model with double masking for participants and investigators. Its primary purpose is treatment-focused, aiming to compare the efficacy and safety of the drugs.
The study began on January 13, 2025, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on June 25, 2025, indicating ongoing recruitment.
This study could significantly impact Amgen’s market position by potentially offering a competitive alternative to Ocrelizumab. Positive results might boost investor confidence and influence stock performance, especially in the context of the competitive multiple sclerosis treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.